334 related articles for article (PubMed ID: 23037633)
21. Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.
Soderquist C; Bagg A
Blood; 2014 Oct; 124(15):2463. PubMed ID: 25436260
[No Abstract] [Full Text] [Related]
22. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
23. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Hochhaus A; La Rosée P; Müller MC; Ernst T; Cross NC
Cell Cycle; 2011 Jan; 10(2):250-60. PubMed ID: 21220945
[TBL] [Abstract][Full Text] [Related]
24. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
25. Gleevec resistance: lessons for target-directed drug development.
Daley GQ
Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
[No Abstract] [Full Text] [Related]
26. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
[TBL] [Abstract][Full Text] [Related]
27. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
28. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
[No Abstract] [Full Text] [Related]
29. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
30. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Jabbour E; Hochhaus A; Cortes J; La Rosée P; Kantarjian HM
Leukemia; 2010 Jan; 24(1):6-12. PubMed ID: 19798095
[TBL] [Abstract][Full Text] [Related]
31. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
32. [Molecular targeting therapy for chronic myeloid leukemia].
Kimura S
Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
[No Abstract] [Full Text] [Related]
33. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
[No Abstract] [Full Text] [Related]
34. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
35. [State of the art in the treatment of chronic leukemias].
Ohnishi K
Rinsho Ketsueki; 2006 Apr; 47(4):278-86. PubMed ID: 16715962
[No Abstract] [Full Text] [Related]
36. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C
Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211
[No Abstract] [Full Text] [Related]
37. A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.
Kuang P; Liu T; Huang Q; Ye Y; Xiang B; Huang J; Diwu L; Wang Y; Meng W; Dong T; Yang S; Lu X
Leuk Res; 2012 Aug; 36(8):e159-62. PubMed ID: 22578778
[No Abstract] [Full Text] [Related]
38. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
39. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Swords R; Alvarado Y; Cortes J; Giles FJ
Curr Hematol Malig Rep; 2007 May; 2(2):83-8. PubMed ID: 20425355
[TBL] [Abstract][Full Text] [Related]
40. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
Grant H; Jiang X; Stebbing J; Foroni L; Craddock C; Griffiths M; Clark RE; O'Brien S; Khorashad JS; Gerrard G; Wang L; Irving JA; Wang M; Karran L; Dyer MJ; Forrest D; Page K; Eaves CJ; Woolfson A
Leukemia; 2010 Oct; 24(10):1817-21. PubMed ID: 20739956
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
